In the largest randomised trial in ESCC, in molecularly unselected patients with advanced stage disease, the addition of the anti-EGFR monoclonal antibody pantitumumab to cisplatin and 5FU chemotherapy did not improve overall survival [18]. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.